Interim safety results from SEPION/AIO-PAK-0118: A multicenter, Phase I/II study of sequential epigenetic and immune targeting in combination with nabpaclitaxel/gemcitabine in patients with advanced pancreatic ductal adenocarcinoma

Jens T. Siveke; Marianne Sinn; Stefan Boeck; Gabriele Siegler; Thomas Seufferlein; Joerg Trojan; Dirk Waldschmidt; Alexander Koenig; Dorothea Schipp; Ines Winkler; Sven Thorsten Liffers; Volker Kunzmann

doi:10.1158/1538-7445.AM2023-CT195

Interim safety results from SEPION/AIO-PAK-0118: A multicenter, Phase I/II study of sequential epigenetic and immune targeting in combination with nabpaclitaxel/gemcitabine in patients with advanced pancreatic ductal adenocarcinoma

Jens T. Siveke, Marianne Sinn, Stefan Boeck, Gabriele Siegler, Thomas Seufferlein, Joerg Trojan, Dirk Waldschmidt, Alexander Koenig, Dorothea Schipp, Ines Winkler, Sven Thorsten Liffers, Volker Kunzmann

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Original Article › peer-review

Original language	Undefined/Unknown
Journal	Cancer Research
DOIs	https://doi.org/10.1158/1538-7445.AM2023-CT195
Publication status	Published - 2023

Access to Document

10.1158/1538-7445.AM2023-CT195

Cite this

Siveke, J. T., Sinn, M., Boeck, S., Siegler, G., Seufferlein, T., Trojan, J., Waldschmidt, D., Koenig, A., Schipp, D., Winkler, I., Liffers, S. T., & Kunzmann, V. (2023). Interim safety results from SEPION/AIO-PAK-0118: A multicenter, Phase I/II study of sequential epigenetic and immune targeting in combination with nabpaclitaxel/gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Cancer Research. https://doi.org/10.1158/1538-7445.AM2023-CT195

@article{81779b9b8df84b088c4615a0987aa04c,

title = "Interim safety results from SEPION/AIO-PAK-0118: A multicenter, Phase I/II study of sequential epigenetic and immune targeting in combination with nabpaclitaxel/gemcitabine in patients with advanced pancreatic ductal adenocarcinoma",

author = "Siveke, {Jens T.} and Marianne Sinn and Stefan Boeck and Gabriele Siegler and Thomas Seufferlein and Joerg Trojan and Dirk Waldschmidt and Alexander Koenig and Dorothea Schipp and Ines Winkler and Liffers, {Sven Thorsten} and Volker Kunzmann",

year = "2023",

doi = "10.1158/1538-7445.AM2023-CT195",

language = "Undefined/Unknown",

journal = "Cancer Research",

publisher = "Amer Assoc Cancer Research",

}

Siveke, JT, Sinn, M, Boeck, S, Siegler, G, Seufferlein, T, Trojan, J, Waldschmidt, D, Koenig, A, Schipp, D, Winkler, I, Liffers, ST & Kunzmann, V 2023, 'Interim safety results from SEPION/AIO-PAK-0118: A multicenter, Phase I/II study of sequential epigenetic and immune targeting in combination with nabpaclitaxel/gemcitabine in patients with advanced pancreatic ductal adenocarcinoma', Cancer Research. https://doi.org/10.1158/1538-7445.AM2023-CT195

Interim safety results from SEPION/AIO-PAK-0118: A multicenter, Phase I/II study of sequential epigenetic and immune targeting in combination with nabpaclitaxel/gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. / Siveke, Jens T.; Sinn, Marianne; Boeck, Stefan et al.
In: Cancer Research, 2023.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Interim safety results from SEPION/AIO-PAK-0118: A multicenter, Phase I/II study of sequential epigenetic and immune targeting in combination with nabpaclitaxel/gemcitabine in patients with advanced pancreatic ductal adenocarcinoma

AU - Siveke, Jens T.

AU - Sinn, Marianne

AU - Boeck, Stefan

AU - Siegler, Gabriele

AU - Seufferlein, Thomas

AU - Trojan, Joerg

AU - Waldschmidt, Dirk

AU - Koenig, Alexander

AU - Schipp, Dorothea

AU - Winkler, Ines

AU - Liffers, Sven Thorsten

AU - Kunzmann, Volker

PY - 2023

Y1 - 2023

UR - https://publons.com/wos-op/publon/65643949/

U2 - 10.1158/1538-7445.AM2023-CT195

DO - 10.1158/1538-7445.AM2023-CT195

M3 - Originalarbeit

JO - Cancer Research

JF - Cancer Research

ER -

Interim safety results from SEPION/AIO-PAK-0118: A multicenter, Phase I/II study of sequential epigenetic and immune targeting in combination with nabpaclitaxel/gemcitabine in patients with advanced pancreatic ductal adenocarcinoma

Access to Document

Other files and links

Cite this